237 related articles for article (PubMed ID: 20855362)
1. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.
Ferrari MD; Färkkilä M; Reuter U; Pilgrim A; Davis C; Krauss M; Diener HC;
Cephalalgia; 2010 Oct; 30(10):1170-8. PubMed ID: 20855362
[TBL] [Abstract][Full Text] [Related]
2. 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks.
Olesen J
Cephalalgia; 2010 Oct; 30(10):1157-8. PubMed ID: 20855360
[No Abstract] [Full Text] [Related]
3. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.
Nelson DL; Phebus LA; Johnson KW; Wainscott DB; Cohen ML; Calligaro DO; Xu YC
Cephalalgia; 2010 Oct; 30(10):1159-69. PubMed ID: 20855361
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment.
Maggioni F; Pini LA; Zanchin G
Cephalalgia; 2011 Jul; 31(9):1061. PubMed ID: 21511951
[No Abstract] [Full Text] [Related]
5. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B; Israel H; Neeb L; Reuter U
Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
[TBL] [Abstract][Full Text] [Related]
7. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.
Tfelt-Hansen PC; Olesen J
J Headache Pain; 2012 Jun; 13(4):271-5. PubMed ID: 22430431
[TBL] [Abstract][Full Text] [Related]
8. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.
Goldstein DJ; Roon KI; Offen WW; Ramadan NM; Phebus LA; Johnson KW; Schaus JM; Ferrari MD
Lancet; 2001 Oct; 358(9289):1230-4. PubMed ID: 11675061
[TBL] [Abstract][Full Text] [Related]
9. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute migraine.
Miller FG
Lancet; 2002 Mar; 359(9308):802. PubMed ID: 11888631
[No Abstract] [Full Text] [Related]
11. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
Färkkilä M; Diener HC; Géraud G; Láinez M; Schoenen J; Harner N; Pilgrim A; Reuter U;
Lancet Neurol; 2012 May; 11(5):405-13. PubMed ID: 22459549
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy and safety of lasmiditan, a novel 5-HT
Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
[TBL] [Abstract][Full Text] [Related]
14. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
[TBL] [Abstract][Full Text] [Related]
15. Lasmiditan for the treatment of migraine.
Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
Goadsby PJ; Wietecha LA; Dennehy EB; Kuca B; Case MG; Aurora SK; Gaul C
Brain; 2019 Jul; 142(7):1894-1904. PubMed ID: 31132795
[TBL] [Abstract][Full Text] [Related]
17. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
[TBL] [Abstract][Full Text] [Related]
18. Targeting the 5-HT
Huang PC; Yang FC; Chang CM; Yang CP
Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
[TBL] [Abstract][Full Text] [Related]
19. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
[No Abstract] [Full Text] [Related]
20. Profiling lasmiditan as a treatment option for migraine.
Curto M; Cipolla F; Cisale GY; Capi M; Spuntarelli V; Guglielmetti M; Martelletti P; Lionetto L
Expert Opin Pharmacother; 2020 Feb; 21(2):147-153. PubMed ID: 31766908
[No Abstract] [Full Text] [Related]
[Next] [New Search]